Diphereline PR

Diphereline PR Caution For Usage

triptorelin

Manufacturer:

Ipsen

Distributor:

Zuellig Pharma
Full Prescribing Info
Caution For Usage
Incompatibilities: 3.75 mg: In absence of incompatibility study, this medicinal product should not be taken with other medicinal products.
11.25 mg: Not applicable.
Special precautions for disposal and other handling: 3.75 mg: The homogenous, milky suspension for injection is reconstituted by gentle shaking. The instructions for reconstitution hereafter and in the leaflet must be strictly followed.
For single use only. Any unused suspension should be discarded.
Used injection needles should be disposed in a designated sharp container. Any remaining product should be discarded.
The powder is to be suspended in 2 ml of mannitol solution: Using one of the injection needles, all of the solvent is drawn up into the injection syringe supplied and transferred to the vial containing the powder. The vial should be gently shaken to completely disperse the powder to obtain a homogenous, milky suspension.
The suspension obtained is then drawn back into the injection syringe. The injection needle should be changed and the suspension should be injected immediately using the needle for injection in the gluteal muscle.
The suspension should be discarded if it is not administered immediately after reconstitution.
11.25 mg: Instructions for use and handling: The powder should be suspended in the specific solvent immediately before injection by shaking the vial gently until a milky homogeneous liquid is obtained (The instructions for reconstitution hereafter and in the leaflet must be strictly followed).
For single use only. Any unused suspension should be discarded.
The powder is to be suspended in 2 ml of mannitol solution: Using the reconstitution needle (without safety device), one of the injection needles, all of the solvent is drawn up into the injection syringe supplied and transferred to the vial containing the powder. The vial should be gently shaken to completely disperse the powder to obtain a homogenous, milky suspension. The suspension obtained is then drawn back into the injection syringe. The injection needle should be changed and the suspension should be injected immediately using the specific needle: the 38 mm length needle (20 G) with safety device for intramuscular injection in the gluteal muscle (men, women, children); the 25 mm length needle (20 G) with safety device for subcutaneous injection in abdomen or thigh (only in men).
The suspension should be discarded if it is not administered immediately after reconstitution. See also Incompatibilities as previously mentioned.
Used injection needles should be disposed in a designated sharp container. Any remaining product should be discarded.
Used needles, unused suspension or other waste material should be disposed of in accordance with local requirements.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in